118 related articles for article (PubMed ID: 26503107)
1. The need for thorough phase II studies in medicines development for Alzheimer's disease.
Gray JA; Fleet D; Winblad B
Alzheimers Res Ther; 2015 Oct; 7(1):67. PubMed ID: 26503107
[TBL] [Abstract][Full Text] [Related]
2. How modeling and simulation have enhanced decision making in new drug development.
Miller R; Ewy W; Corrigan BW; Ouellet D; Hermann D; Kowalski KG; Lockwood P; Koup JR; Donevan S; El-Kattan A; Li CS; Werth JL; Feltner DE; Lalonde RL
J Pharmacokinet Pharmacodyn; 2005 Apr; 32(2):185-97. PubMed ID: 16283534
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers in Alzheimer's disease drug development.
Cummings JL
Alzheimers Dement; 2011 May; 7(3):e13-44. PubMed ID: 21550318
[TBL] [Abstract][Full Text] [Related]
4. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.
Roses AD
Neuropsychopharmacology; 2009 Jan; 34(1):6-17. PubMed ID: 18923406
[TBL] [Abstract][Full Text] [Related]
5. Improving Alzheimer's disease phase II clinical trials.
Greenberg BD; Carrillo MC; Ryan JM; Gold M; Gallagher K; Grundman M; Berman RM; Ashwood T; Siemers ER
Alzheimers Dement; 2013 Jan; 9(1):39-49. PubMed ID: 23164548
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers for the early stages of clinical development in Alzheimer's disease.
Bordet R; Dartigues JF; Dubois B; Goehrs JM; Vernoux L; Semah F; Pasquier F; Bidaut-Mazel C;
Therapie; 2010; 65(4):285-90, 277-283. PubMed ID: 20854749
[TBL] [Abstract][Full Text] [Related]
7. Commentary on "Biomarkers in Alzheimer's disease drug development." The view from Alzheimer's Disease Neuroimaging Initiative.
Weiner MW
Alzheimers Dement; 2011 May; 7(3):e45-7. PubMed ID: 21575867
[No Abstract] [Full Text] [Related]
8. Drugs in clinical development for Alzheimer's disease: summary and table.
Drugs Aging; 2012 Jan; 29(1):73-9. PubMed ID: 22191726
[No Abstract] [Full Text] [Related]
9. Commentary on "Biomarkers in Alzheimer's disease drug development." Can't live without 'em.
Aisen PS
Alzheimers Dement; 2011 May; 7(3):e48-50. PubMed ID: 21575868
[No Abstract] [Full Text] [Related]
10. Alzheimer's disease amyloid hypothesis at crossroads: where do we go from here?
Saxena U
Expert Opin Ther Targets; 2010 Dec; 14(12):1273-7. PubMed ID: 21058918
[TBL] [Abstract][Full Text] [Related]
11. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease).
Roses AD; Saunders AM; Huang Y; Strum J; Weisgraber KH; Mahley RW
Pharmacogenomics J; 2007 Feb; 7(1):10-28. PubMed ID: 16770341
[TBL] [Abstract][Full Text] [Related]
12. The use of mechanistic biomarkers for evaluating investigational CNS compounds in early drug development.
Soares HD
Curr Opin Investig Drugs; 2010 Jul; 11(7):795-801. PubMed ID: 20571975
[TBL] [Abstract][Full Text] [Related]
13. Solanezumab for the treatment of mild-to-moderate Alzheimer's disease.
Imbimbo BP; Ottonello S; Frisardi V; Solfrizzi V; Greco A; Seripa D; Pilotto A; Panza F
Expert Rev Clin Immunol; 2012 Feb; 8(2):135-49. PubMed ID: 22288451
[TBL] [Abstract][Full Text] [Related]
14. New and emerging treatments for Alzheimer's disease.
Corbett A; Ballard C
Expert Opin Emerg Drugs; 2012 Jun; 17(2):147-56. PubMed ID: 22439621
[TBL] [Abstract][Full Text] [Related]
15. Risk in CNS drug discovery: focus on treatment of Alzheimer's disease.
Pritchard JF
BMC Neurosci; 2008 Dec; 9 Suppl 3(Suppl 3):S1. PubMed ID: 19090998
[TBL] [Abstract][Full Text] [Related]
16. Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials.
Vandenberghe R; Rinne JO; Boada M; Katayama S; Scheltens P; Vellas B; Tuchman M; Gass A; Fiebach JB; Hill D; Lobello K; Li D; McRae T; Lucas P; Evans I; Booth K; Luscan G; Wyman BT; Hua L; Yang L; Brashear HR; Black RS;
Alzheimers Res Ther; 2016 May; 8(1):18. PubMed ID: 27176461
[TBL] [Abstract][Full Text] [Related]
17. Value-Generating Exploratory Trials in Neurodegenerative Dementias.
Friedman LG; McKeehan N; Hara Y; Cummings JL; Matthews DC; Zhu J; Mohs RC; Wang D; Hendrix SB; Quintana M; Schneider LS; Grundman M; Dickson SP; Feldman HH; Jaeger J; Finger EC; Ryan JM; Niehoff D; Dickinson SL; Markowitz JT; Owen M; Travaglia A; Fillit HM
Neurology; 2021 May; 96(20):944-954. PubMed ID: 33674360
[TBL] [Abstract][Full Text] [Related]
18. Optimizing phase II of drug development for disease-modifying compounds.
Cummings JL
Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S15-20. PubMed ID: 18631992
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological approaches for Alzheimer's disease: neurotransmitter as drug targets.
Prakash A; Kalra J; Mani V; Ramasamy K; Majeed AB
Expert Rev Neurother; 2015 Jan; 15(1):53-71. PubMed ID: 25495260
[TBL] [Abstract][Full Text] [Related]
20. Accelerating Medicines Partnership: Alzheimer's Disease (AMP-AD) Knowledge Portal Aids Alzheimer's Drug Discovery through Open Data Sharing.
Hodes RJ; Buckholtz N
Expert Opin Ther Targets; 2016; 20(4):389-91. PubMed ID: 26853544
[No Abstract] [Full Text] [Related]
[Next] [New Search]
